Results 151 to 160 of about 50,964 (281)

Cervical Skip Metastases and Extensive Central Venous Thrombosis as the Initial Presentation of High‐Grade Prostate Adenocarcinoma With Discordant PI‐RADS 3 Findings: A Case Report and Diagnostic Challenge

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Prostate cancer can initially present with cervical lymph node “skip” metastases and extensive central venous thrombosis, without pelvic or bone involvement. A PI‐RADS 3 lesion on mpMRI does not exclude high‐grade (Gleason 5 + 5 = 10) disease. Unexplained thrombosis in elderly men warrants prostate cancer investigation.
Yuchun Luo, Benhui Lai, Juncheng Huang
wiley   +1 more source

Genetic ancestry–concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration‐resistant prostate cancer

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background The authors observed differences in response between Black and White patients with metastatic castration‐resistant prostate cancer (mCRPC) who were treated prospectively with androgen receptor pathway inhibition (ARPI) in the Abi Race and PANTHER studies.
Sean A. Piwarski, Lauren E. Howard, Morgan A. Paul, Nick Bachelder, Bonnie LaCroix, Angela Clayton, Donna Allen, Julie Kephart, Andrew J. Armstrong, Steven R. Patierno, Daniel J. George, Terry Hyslop, Jennifer A. Freedman   +12 more
wiley   +1 more source

Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high‐risk prostate cancer: A predictive biomarker analysis

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background Prostate cancer (PC) arising in patients with low testosterone is often more aggressive and less responsive to androgen deprivation therapy (ADT). This study evaluated whether baseline testosterone group (low vs. normal) modifies the mortality benefit of adding docetaxel to radiation therapy (RT) and ADT in nonmetastatic high‐risk ...
Johnathan Zeng, Ming‐Hui Chen, Jing Wu, Wanling Xie, Praful Ravi, Paul Nguyen, Howard Sandler, Anthony V. D’Amico   +7 more
wiley   +1 more source

Cuprous oxide nanoparticles inhibit prostate cancer by attenuating the stemness of cancer cells via inhibition of the Wnt signaling pathway

International Journal of Nanomedicine, 2017
Ye Wang,1,* Qi-Wei Yang,1,2,* Qing Yang,2,* Tie Zhou,1 Min-Feng Shi,1,3 Chen-Xia Sun,4 Xiu-Xia Gao,4 Yan-Qiong Cheng,1 Xin-Gang Cui,2 Ying-Hao Sun1 1Department of Urology, Changhai Hospital, 2Department of Urology, The Third Affiliated Hospital ...
Wang Y, Yang QW, Yang Q, Zhou T, Shi MF, Sun CX, Gao XX, Cheng YQ, Cui XG, Sun YH   +9 more
doaj  

MITF Gain‐of‐Function Mutation in Metastatic Prostate Cancer: A Rare Finding With Potential Therapeutic Significance

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Prostate cancer is the most common non‐cutaneous malignancy in men and remains a leading cause of cancer‐related mortality, particularly in aggressive variants. These tumors are usually associated with alterations in TP53, RB1, and PTEN.
Paul J. Pecorin, Nyembezi Dhliwayo, Matthew Demetrious, Ludimila Cavalcante, Veronica Rodriguez‐Bravo, Josep Domingo‐Domenech, Thomas Westbrook   +6 more
wiley   +1 more source

Lysine lactylation‐mediated post‐translational modification: Molecular mechanisms and therapeutic target exploration in tumour drug resistance

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
Lysine lactylation (Kla) serves as a metabolic–epigenetic switch governed by writer–eraser–reader regulatory systems, directly connecting the Warburg effect to diverse forms of tumour drug resistance. Intratumoural lactylation critically contributes to treatment failure in chemotherapy, targeted therapy and immunotherapy.
Juan Li, Yan Shang, Haojie Wu, Shenglong Yang, Maiqun Zuo, Hailong Zhao   +5 more
wiley   +1 more source

The role of the adipokine chemerin in prostate cancer [PDF]

Obesity is a major health problem worldwide and its effects on the cardiovascular system are well documented. It also leads to the development of metabolic disease such as insulin resistance and diabetes.
Williams, Kevin George
core  

Vacuolization as a Novel Approach to Cancer Therapy

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 6, June 2026.
This review discusses the novel strategy of inducing vacuole formation in cancer cells using small molecules, that induce nonapoptotic cell death mechanisms, such as paraptosis, oncosis, autophagy, and methuosis, and its potential in overcoming resistance to apoptosis‐based cancer therapies.
Mariah Pasternak, Noor Hussein, Veronica Piedra, Saloni Malla, Chandrabose Karthikeyan, Haneen Amawi, Harish Rajak, Charles R. Ashby Jr., R. Jayachandra Babu, Amit K. Tiwari   +9 more
wiley   +1 more source

Future Treatment Possibilities of Castration-Resistant Prostate Cancer

, 2014
I discuss treatment possibilities of prostate cancers that don't respond to the hormonal deprivation therapy. In the patients that need these treatment, after castration (deprivation of hormonal Stimulation), cancer progression is still noticed.
Alex-Ohunyon, Osekpamen
core  

Dynamic Profiling of Circulating Tumor Cells and MYC/PTEN Alterations in Prostate Cancer Patients Undergoing Radical Prostatectomy in Amazon Population

Molecular Carcinogenesis, Volume 65, Issue 6, Page 665-676, June 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed malignancy among men and the sixth leading cause of cancer‐related mortality worldwide. Radical prostatectomy remains the standard treatment for localized disease; however, approximately one‐third of patients develop biochemical recurrence within 10 years. Although prostate‐specific
Juliana Ramos Chaves, Rommel Mario Rodriguez Burbano, Amanda de Nazaré Cohen‐Paes, Diego Di Felipe Ávila Alcântara, Ana Paula Borges de Souza, Maria Janete Nahum Gomes, Sérgio Augusto Antunes Ramos, André Salim Khayat   +7 more
wiley   +1 more source